Last reviewed · How we verify
Rubidium-82
Rubidium-82 is a positron-emitting radioisotope that accumulates in myocardial tissue proportional to blood flow, allowing visualization of cardiac perfusion via PET imaging.
Rubidium-82 is a positron-emitting radioisotope that accumulates in myocardial tissue proportional to blood flow, allowing visualization of cardiac perfusion via PET imaging. Used for Myocardial perfusion imaging for detection of coronary artery disease, Assessment of myocardial viability in patients with coronary artery disease.
At a glance
| Generic name | Rubidium-82 |
|---|---|
| Also known as | Myocardial Perfusion PET, CardioGen-82 |
| Sponsor | Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC) |
| Drug class | PET radiopharmaceutical |
| Target | Na+/K+-ATPase pump (myocardial uptake mechanism) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Rubidium-82 is produced from a strontium-82/rubidium-82 generator and behaves similarly to potassium, being taken up by viable myocardium via Na+/K+-ATPase pumps. The positron emissions are detected by PET cameras to create real-time images of myocardial perfusion at rest and during stress, enabling assessment of coronary artery disease and myocardial viability.
Approved indications
- Myocardial perfusion imaging for detection of coronary artery disease
- Assessment of myocardial viability in patients with coronary artery disease
Common side effects
- Radiation exposure (minimal, diagnostic dose)
- Headache
- Dizziness
- Chest discomfort (stress-induced)
Key clinical trials
- 18F-mFBG Imaging for Myocardial Sympathetic Innervation (PHASE2)
- Dynamic 82-Rb Positron Emission Tomography (PET) for the Grading of KIDney Carcinoma (PHASE2)
- Parathyroid Adenoma Detection With Rubidium-82 Imaging
- Positron Emission Tomography to Assess the Effect of Camzyos on Ischaemia in HOCM: PEACH Trial (NA)
- Cadmium-zinc-telluride (CZT) Imaging of Myocardial Blood Flow (MBF) (SPECT MBF) (NA)
- Spironolactone Therapy in Chronic Stable Right HF Trial (PHASE4)
- Study of Cardiac Lesions Angiogenesis by 68Ga-NODAGA-RGD Cardiac PET (NA)
- Dose Optimization for Rubidium PET Imaging in Patients With Known or Suspected Ischemic Heart Disease
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: